8-K: VSee Health Secures $6M in Private Placement Offering

VSee Health, Inc. announced a private placement of common stock, pre-funded warrants, and common warrants, raising approximately $6 million for working capital.

Summary

• VSee Health, Inc. entered into a Securities Purchase Agreement on November 25, 2025, with a single institutional and accredited investor.
• The company will sell 9,836,065 shares of common stock or pre-funded warrants, along with common warrants to purchase up to 19,672,130 shares of common stock.
• The private placement is expected to generate gross proceeds of approximately $6 million.
• The purchase price for each share (or pre-funded warrant) and accompanying common warrants is $0.61.
• The common warrants will have an exercise price of $0.61 per share and will expire five years from their initial exercise date, subject to stockholder approval.
• Net proceeds are intended for working capital and general corporate purposes.
• A.G.P./Alliance Global Partners acted as the placement agent, receiving a 7% cash fee of gross proceeds, plus up to $50,000 for legal fees and $10,000 for non-accountable expenses.

Sentiment

Score: 6

Explanation: The capital raise provides necessary funding for working capital and general corporate purposes, which is a positive. However, the significant potential for dilution from the warrants and the associated fees temper the overall positive sentiment. The need for stockholder approval for the warrants also introduces a minor uncertainty.

Positives

• Secured approximately $6 million in gross proceeds, providing capital for working capital and general corporate purposes.
• The capital raise is from a single institutional and accredited investor, indicating confidence from a sophisticated party.
• The company will file a registration statement for resale, potentially increasing liquidity for investors in the future.

Negatives

• Significant potential for dilution from the issuance of 9,836,065 shares (or pre-funded warrants) and up to 19,672,130 common warrants.
• Placement agent fees of 7% of gross proceeds ($420,000) and additional expenses ($60,000) reduce net proceeds.
• Stockholder approval is required for the common warrants and underlying shares, introducing a potential hurdle.
• The company acknowledges that the issuance of securities may result in substantial dilution of outstanding common stock.

Risks

• Failure to obtain stockholder approval for the issuance of common warrants and underlying shares could impact the deal terms or the company's ability to raise capital effectively.
• The company's common stock is currently subject to delisting by the Trading Market.
• Purchasers may engage in hedging activities, including short sales, which could negatively impact the market price of the company's publicly-traded securities.
• Potential for material adverse effect on the company's business, financial condition, or results of operations.
• Risk of not maintaining listing or quotation of Common Stock on the Trading Market.
• Risk of not being able to renew existing insurance coverage or obtain similar coverage.
• Risk of litigation or regulatory actions.

Future Outlook

The company intends to use the net proceeds from the offering for working capital and general corporate purposes. It plans to file a registration statement for the resale of the issued securities within 20 calendar days of closing and aims for it to be effective within 60 to 90 days. Stockholder approval for the common warrants is required within 90 days of closing, with subsequent meetings every 90 days if not initially approved. Executive officers and directors will be subject to a 90-day lock-up period after the registration statement becomes effective.

Management Comments

• The Company currently intends to use the net proceeds from the Offering for working capital and general corporate purposes.
• The Company acknowledges that the issuance of the Securities may result in dilution of the outstanding shares of Common Stock, which dilution may be substantial under certain market conditions.

Industry Context

This private placement reflects a common strategy for smaller public companies to raise capital from institutional investors, especially when public market conditions are challenging or when seeking to avoid the complexities and costs of a registered public offering. The issuance of warrants is typical in such deals to provide additional upside potential to investors, though it also introduces future dilution risk. The requirement for stockholder approval for the warrants and the lock-up agreements are standard provisions aimed at protecting existing shareholders and ensuring market stability post-offering.

Comparison to Industry Standards

• The 7% placement agent fee is within the typical range for private placements of this size, which can vary from 5% to 10% depending on the company's size, market capitalization, and perceived risk.
• The issuance of warrants at 200% of the shares purchased (19.67M warrants for 9.83M shares) is a relatively high warrant coverage, often seen in deals with smaller companies or those perceived as higher risk, offering more upside to investors.
• The $0.61 exercise price for the common warrants, matching the purchase price, is common, but the pre-funded warrants with a nominal $0.0001 exercise price are designed to allow investors to acquire shares immediately without exceeding beneficial ownership limits, a standard structure for institutional investors.
• The 90-day lock-up for management and the company's restriction on future equity sales for 90 days post-effectiveness are standard market practice to prevent immediate downward pressure on the stock price following the offering and registration.
• The beneficial ownership limitation of 4.99% or 9.99% is a standard provision to prevent investors from triggering Section 13(d) reporting requirements or other control-related regulations.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for significant dilution from the issuance of new shares and warrants. The capital raise provides funding for operations, which could support long-term value, but the immediate impact is dilutive.
• Investors (Purchaser): Gains equity and warrant positions at a specified price, with potential for future upside. The pre-funded warrants offer flexibility regarding beneficial ownership limits.
• Employees/Management: Subject to lock-up agreements, aligning their interests with the company's post-offering performance.
• Company Operations: The $6 million in gross proceeds will be used for working capital and general corporate purposes, supporting ongoing operations and strategic initiatives.

Next Steps

• Closing of the offering, expected on or about December 1, 2025.
• Company to file a registration statement for resale of the Shares, Pre-Funded Warrant Shares, and Warrant Shares within 20 calendar days following the closing.
• Company to use commercially reasonable efforts to cause the registration statement to be declared effective by the SEC within 60 days (or 90 days if reviewed).
• Company to hold a meeting of stockholders within 90 days of closing to obtain approval for the issuance of the common warrants and underlying shares.
• Executive officers and directors will enter into 90-day lock-up agreements.

Key Dates

Recommendation

While the $6 million capital raise provides VSee Health with much-needed working capital and general corporate funds, which is a positive for its operational stability, the significant potential for dilution from the issuance of new shares and a large number of warrants (up to 200% coverage) is a concern. The stock is also noted as being subject to delisting, adding to market uncertainty. The terms of the private placement, including fees and warrant structure, are typical for a company of this profile seeking capital, suggesting it's an expected financing event rather than a strong indicator of future outperformance. Investors should hold to monitor the company's execution with the new capital, the outcome of the stockholder approval for the warrants, and progress on its listing status before making further investment decisions.

Keywords

VSee Health, Private Placement, Common Stock, Warrants, Pre-Funded Warrants, Capital Raise, SEC Filing, 8-K, Equity Financing, Dilution, Stockholder Approval, A.G.P./Alliance Global Partners